Evidence map›Paper›PMID 41695436›Full record

ArticleFrontiers in allergy2026

The Spanish REAL project: expert allergist guidance on allergen immunotherapy based on mixtures from different allergenic sources.

M Viñas, V Bellido, D El-Qutob, F García, T W Jimenez-Rodriguez, M Rial, J M Vega-Chicote, J Cuesta-Herranz

Abstract read
In one paragraph

Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

M ViñasAllergy Department, Consorci Sanitari de Terrassa, Hospital Universitari de Terrassa, Barcelona, Spain.
V BellidoAllergy Department, Hospital El Tomillar, Alcalá de Guadaira, Sevilla, Spain.
D El-QutobInternal Medicine Department, Hospital Universitario de La Plana de Vila-real, Castellón, Spain.
F GarcíaAllergy Department, Instituto Investigacion Sanitaria Biobizkaia, Hospital Universitario de Basurto, Bilbao, Spain.
T W Jimenez-RodriguezAllergy Section, Dr. Balmis General University Hospital; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
M RialAllergy Department, Complexo Hospitalario Universitario de Ferrol, Ferrol (A Coruña), Spain.
J M Vega-ChicoteAllergy Department, Hospital Regional Universitario de Málaga, Málaga, Spain.
J Cuesta-HerranzAllergy Department, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The increase in polyallergy highlights allergen-specific immunotherapy (AIT) as a crucial therapeutic option for these patients. It is the only etiological treatment capable of modifying the natural course of allergic diseases. Its use, particularly with mixtures from different allergenic sources, varies across regions. In Spain, geographic and environmental diversity leads to complex, heterogeneous sensitization patterns not fully addressed by international guidelines, reinforcing the need for context-specific recommendations integrating current evidence and real clinical practice. Objective: To establish general recommendations for managing polyallergic patients undergoing AIT with mixtures of different allergenic sources in Spain. Methodology: Eight regional meetings with 61 experts were held across Spain using the Workmat® methodology: evidence-based exercises designed to facilitate discussion and consistent data collection. Results: Experts agreed that polymerized allergen extract mixtures offer several advantages over AIT with simultaneous use of individual allergen extracts, as they allow multiple sensitizations to be treated in a single application, simplifying the treatment without compromising safety or efficacy while also saving time and costs and improving treatment adherence. Furthermore, the use of polymerized allergen extracts has improved efficacy and safety in AIT. It is essential to perform an individualized evaluation, according to the type of extract, the mixture, and the patient's comorbidities. Conclusion: The increasing prevalence of polyallergy has emerged as a growing challenge in routine clinical practice. In this context, AIT using polymerized allergen extract mixtures, at optimal doses, tailored to individual sensitization profiles represent a practical and effective approach for managing polyallergy in the Spanish clinical setting.

Indexed as

allergen immunotherapy (AIT)immunotherapy mixturespolyallergypolymerized extractpolysensitizationpolysensitized

Identifiers

PMID41695436
PMCPMC12900685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.